Monomeric DAPTA

Drug Profile

Monomeric DAPTA

Alternative Names: Adaptavir; mDAPTA; Monomeric (D-Alanine1) Peptide T amide; RAP-101

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RAPID Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Antivirals; Peptides; Small molecules
  • Mechanism of Action CCR5 receptor antagonists; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Progressive multifocal leukoencephalopathy
  • No development reported Hepatitis B; HIV infections

Most Recent Events

  • 24 Sep 2015 No recent reports on development identified - Phase-II for HIV infections in USA (Intranasal)
  • 21 Mar 2011 Efficacy data from a Phase-II trial in HIV infections released by RAPID Pharmaceuticals
  • 21 Mar 2011 RAPID Pharmaceuticals completes a Phase-II trial in HIV infections in USA (NCT00951743)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top